Group 1 - The Hong Kong Stock Exchange's innovative drug-focused ETF (520690) has officially launched, closely tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on leading innovative drug companies and high liquidity, research-intensive stocks [1] - Key weighted stocks in the index include BeiGene, Innovent Biologics, WuXi Biologics, CanSino Biologics, CSPC Pharmaceutical Group, China National Pharmaceutical Group, 3SBio, Hansoh Pharmaceutical, Zai Lab, and WuXi AppTec [1] - As of July 31, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has seen a year-to-date increase of 101.58% [1] Group 2 - Industry experts believe that China's innovative drug industry is undergoing a strategic leap from quantitative to qualitative changes, driven by demographic shifts, policy benefits, and technological breakthroughs [1] - The Chinese pharmaceutical innovation ecosystem is transitioning from "following innovation" to "leading innovation," marking a historic transformation [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index serves as the first precise index tool focused on this sector, providing investors with an efficient means to participate in this transformation through rigorous compilation rules and dynamic optimization mechanisms [1] Group 3 - With ongoing policy benefits, emerging corporate profit inflection points, and strengthening global competitiveness, the index is expected to become a core allocation target for sharing the dividends of China's pharmaceutical innovation [1]

Investment Rating - The report maintains an "Outperform" rating for multiple leading innovative drug companies and CXOs in the healthcare sector [2]. Core Insights - The report emphasizes a sustained positive outlook on the innovative drug industry and its supply chain, highlighting the importance of increasing allocations to leading companies in this space [4][6]. - The performance of the Hong Kong stock picks portfolio showed an average increase of 27.1% in July 2025, outperforming the Hang Seng Healthcare Index, which rose by 22.8% [5][9]. - Major business development (BD) and merger & acquisition (M&A) activities in the innovative drug sector are ongoing, with significant deals reported, indicating a robust market environment [6][35][36]. Summary by Sections Investment Focus - The report lists several companies with an "Outperform" rating, including 恒瑞医药 (Hengrui Pharmaceuticals), 迈瑞医疗 (Mindray), 药明康德 (WuXi AppTec), and others [2]. Performance Analysis - The July 2025 Hong Kong stock picks portfolio included companies like 信达生物 (Innovent Biologics) and 百济神州 (BeiGene), with top performers showing significant gains, such as 映恩生物 (DualityBio) at +48.0% [5][10]. - The healthcare sector in Hong Kong saw notable gains, with companies like 华检医疗 (IVD Medical) and 加科思-B (Jacobio Pharmaceuticals) leading the way [6][34]. Market Trends - The report highlights a recovery in the global innovative drug sector, with leading CXO firms like 药明合联 (WuXi XDC) and 药明康德 (WuXi AppTec) reporting strong earnings growth [7][37]. - Optimized centralized procurement policies and steady progress in innovative drug reimbursement are noted, with over 100 drugs applying for inclusion in the innovative drug reimbursement list [7][38][39]. Company-Specific Insights - 石药集团 (CSPC) and 中国生物制药 (Sino Biopharmaceutical) are newly added to the top picks, with strong potential in their respective innovative drug pipelines [4][32]. - The report discusses the promising clinical pipelines of companies like 三生制药 (3SBio) and 信达生物 (Innovent Biologics), indicating robust growth prospects [18][23].

Core Viewpoint - The report from CMB International initiates coverage on China Biopharmaceutical (01177) with a "Buy" rating, setting a target price of HKD 9.40 based on a 10-year DCF model with a WACC of 9.3% and a perpetual growth rate of 2.0% [1] Group 1: Financial Projections - Revenue is expected to grow by 11.4%/10.5%/9.6% in 2025E/26E/27E, while adjusted net profit is projected to increase by 12.2%/11.5%/10.5% during the same period [1] Group 2: Innovation and R&D - The company is significantly increasing its R&D investment, with an expected 17.6% of revenue allocated to R&D in 2024, up from 9.9% in 2019 [1] - By the end of 2024, the company will have received approval for 17 innovative drugs, with innovative product revenue accounting for 42% of total revenue, compared to 11% in 2015 [1] - The company has been actively engaging in License in transactions, averaging over 3 deals per year from 2019 to 2024, enhancing its innovative drug pipeline [1] Group 3: Product Pipeline and Market Potential - The company has several products with potential for overseas licensing collaborations, including TQC3721, Rovafixitinib, TQB2102, TQB3616, TQA2225, LM-108, LM-168, and LM-364 [1] - The innovative R&D focuses on four key areas: oncology, liver disease/metabolism, respiratory, and surgical/pain management, with a rich pipeline of innovative drugs [2] - Anlotinib has become a cornerstone product with 9 approved indications and 4 NDA submissions, further expanding its sales potential through combination therapies [2] Group 4: Biosimilars and Generic Drugs - The company has 7 approved biosimilars with a total market capacity of RMB 24 billion in 2024, and sales are expected to grow rapidly, particularly for the first generic version of Pertuzumab [3] - The chemical generic drug business has shown resilience during recent policy adjustments, with a projected revenue growth of 3.1% YoY in 2024 [3] - The impact of centralized procurement on generic drugs has largely dissipated, with the tenth batch of centralized procurement accounting for only 1% of the company's total revenue in 2024 [3]

Core Viewpoint - 招银国际 initiates coverage on China Biopharmaceutical (01177) with a "Buy" rating, setting a target price of HKD 9.40 based on a 10-year DCF model with a WACC of 9.3% and a perpetual growth rate of 2.0% [1] Group 1: Innovation and R&D - The company is undergoing a comprehensive transformation towards innovation, with R&D expenditure expected to account for 17.6% of revenue in 2024, up from 9.9% in 2019 [2] - By the end of 2024, the company will have received approval for 17 innovative drugs, with innovative product revenue contributing 42% of total revenue, compared to 11% in 2015 [2] - The company has increased its focus on License in transactions, averaging over 3 deals per year from 2019 to 2024, enhancing its innovative drug pipeline [2] Group 2: Product Pipeline and Market Potential - The company’s innovative R&D focuses on four key areas: oncology, liver disease/metabolism, respiratory, and surgical/pain management, resulting in a rich pipeline [3] - Anlotinib has become a cornerstone product in oncology, with 9 approved indications and 4 NDA submissions as of July 2025, and is expected to expand into first-line treatment through combination with immunotherapy [3] - The company has several products with potential for overseas licensing, including TQC3721, Rovafatinib, TQB2102, and others, indicating strong prospects for international collaboration [2][3] Group 3: Biosimilars and Generic Drugs - The company has received approval for 7 biosimilars, with a total market capacity of RMB 24 billion in 2024, and is expected to see rapid sales growth, particularly for the first biosimilar of Pertuzumab [4] - The chemical generic drug business has shown resilience during recent policy adjustments, with a projected revenue growth of 3.1% YoY in 2024 [4] - The impact of generic drug procurement policies has largely dissipated, with the tenth batch of procurement accounting for only 1% of the company’s total revenue in 2024 [4]

Investment Rating - The report initiates coverage with a "Buy" rating and sets a target price of HKD 9.40, indicating a potential upside of 24.9% from the current price of HKD 7.52 [1][3][23]. Core Insights - The report highlights the significant achievements of the company in its transformation from generic to innovative pharmaceuticals, focusing on key therapeutic areas such as oncology, liver disease/metabolism, respiratory, and surgical/pain management [1][9][26]. - The company has increased its R&D investment, with R&D expenses projected to reach RMB 5.09 billion in 2024, accounting for 17.6% of revenue, up from 9.9% in 2019 [10][40]. - The innovative product pipeline has expanded significantly, with 17 approved innovative drugs by the end of 2024, and the revenue contribution from innovative products is expected to reach 50% by 2025 and 60% by 2027 [10][47]. Financial Summary - For FY23A, the company reported sales revenue of RMB 26.199 billion, with a projected growth of 10.2% in FY24A [2]. - Adjusted net profit for FY23A was RMB 2.589 billion, with an expected increase of 33.5% in FY24A [2]. - The adjusted earnings per share (EPS) is forecasted to grow from RMB 0.14 in FY23A to RMB 0.19 in FY24A [2]. Market Performance - The company's market capitalization is approximately HKD 141.08 billion, with an average trading volume of HKD 860.8 million in March [3]. - The stock has shown strong performance, with a 166.7% increase over the past six months [5]. Product Pipeline and Innovation - The company has a robust pipeline with multiple products showing potential for overseas licensing, including TQC3721, 罗伐昔替尼, and TQB2102 [12][27]. - The oncology segment is highlighted as a key growth area, with 安罗替尼 being a cornerstone product that has received multiple indications and is expected to generate significant sales [13][14]. Business Strategy - The company is focusing on enhancing its supply chain and production efficiency, achieving a procurement coverage rate of 95% by 2024 [28]. - A strategic shift towards a more specialized sales structure has been implemented to improve marketing effectiveness and operational efficiency [33]. Growth Projections - Revenue is expected to grow at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2027, driven by innovative product sales and a strong pipeline [23][24]. - Adjusted net profit is projected to increase at a CAGR of 11.4% during the same period [24].

威胜控股(03393.HK)：威胜信息上半年营业收入13.68亿元，同比增加11.88%；归母净利润3.05亿元，同 比增加12.24%。 盈大地产(00432.HK)：上半年综合收入7.36亿港元，同比增长35%；净亏损约2.49亿港元，同比扩大 62.75%。 澳能建设(01183.HK)：发布盈喜，预计上半年纯利同比增超125%至不少于1800万澳门元。 金融界7月31日消息，周四港股指数低开后震荡冲高，午后再度跳水下挫维持震荡走势，截止收盘，恒 生指数跌1.6%报24773.33点，恒生科技指数跌0.69%报5453.14点，国企指数跌1.72%报8882.95点，红筹 指数跌2.29%报4249.7点。 盘面上，大型科技股多下挫，阿里巴巴跌1.2%，腾讯控股涨0.18%，京东集团跌3.15%，小米集团跌 2.92%，网易跌0.39%，美团跌4.55%，哔哩哔哩涨0.28%；黄金股、内房股跌幅居前，老铺黄金跌超 8%，碧桂园、万科企业跌超7%，龙湖集团跌超6%，山东黄金跌近4%。AI应用板块表现强势，半导体 板块午后拉升，快手涨6.35%，中芯国际涨1.79%，鞍钢股份收跌7.79%。 企业新闻 圣贝 ...

Group 1 - The core viewpoint of the article highlights the recent performance of the innovative drug ETF Guotai (517110), which has seen a net inflow for four consecutive days and a year-to-date increase of over 50% [1] - Leading pharmaceutical companies in China, such as Three-Sixty Pharmaceutical and China National Pharmaceutical Group, have secured significant overseas contracts, indicating a growing trend in the international market for Chinese innovative drugs [1] - On July 28, 2025, Heng Rui Pharmaceutical announced an agreement with GSK to grant global exclusive rights for the HRS-9821 project and up to 11 additional projects, with an initial payment of $500 million from GSK, and potential milestone payments totaling approximately $12 billion [1] Group 2 - The collaboration model between Heng Rui and GSK, which involves shared risks and benefits, sets a new paradigm for the international expansion of Chinese innovative drugs [1] - Continuous policy support in the industry is expected to lead to an increase in both profitability and valuation for the sector [1] - The integration of artificial intelligence is anticipated to further enhance market sentiment and valuation within the innovative drug sector, making the innovative drug ETF (517110) a potential long-term investment opportunity [1]

Market Overview - The Hong Kong stock market showed mixed performance, with the Hang Seng Index down 1.07% to 24,906.39 points, while the Hang Seng Tech Index rose 0.34% to 5,509.61 points [1] - Major technology stocks experienced fluctuations, with Kuaishou surging over 8% and Tencent rising 1.5%, while Meituan fell over 3% [1] - There was a notable shift of funds from gold ETFs to domestic stocks, leading to significant declines in gold stocks [1] Company News - New Oriental reported a net revenue of $4.9 billion for the fiscal year 2025, a year-on-year increase of 13.6%, and a net profit of $372 million, up 20.1% [2][4] - Vanke Enterprises secured a loan of 869 million RMB from Shenzhen Metro Group [3] - CATL achieved revenue of 178.886 billion RMB in the first half of the year, a 7.27% increase year-on-year, with a net profit of 30.512 billion RMB, up 33.02% [3] - Weisheng Holdings reported a revenue of 1.368 billion RMB for the first half of the year, an 11.88% increase, and a net profit of 305 million RMB, up 12.24% [4] - Yingda Real Estate reported a comprehensive income of 736 million HKD for the first half of the year, a 35% increase, but a net loss of approximately 249 million HKD, widening by 62.75% year-on-year [4] - Aon Construction expects a net profit increase of over 125% for the first half of the year, reaching at least 18 million MOP [5] - Da Cheng Corn Group issued a profit warning, anticipating a net loss of approximately 65 to 85 million HKD for the first half of the year [6] - China Biopharmaceutical announced successful external authorization cooperation for LM-299, with a milestone payment of $300 million expected soon [7] Industry Insights - CITIC Securities noted an increase in confidence in certain sub-sectors, with earnings expectations being revised upwards ahead of earnings reports, particularly in new energy vehicles, semiconductors, and consumer electronics [9] - Zhongtai International indicated that the overall upward trend in the Hong Kong stock market remains healthy, with a shift from risk-averse sentiment to improved fundamentals and positive policy expectations [9] - Ping An Securities highlighted the low valuation of the Hong Kong market and the increasing trading activity under the "profit-making effect," maintaining an optimistic long-term outlook [10] - Huatai Securities expressed confidence in the opportunities within the Hong Kong market, particularly in the Hang Seng Tech Index, citing the potential for further appreciation of the RMB and the attractiveness of Chinese assets globally [10]

Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (159570) has seen significant inflows and growth, indicating strong investor interest in the innovative drug sector [1][5]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) opened with a surge, rising over 2% with a trading volume exceeding 900 million yuan, and net inflows surpassing 770 million yuan in the last two days [1]. - As of July 30, the ETF's latest scale exceeded 11.9 billion yuan, setting a new historical record and leading in scale and liquidity among its peers [1]. Group 2: Index Composition - The majority of the constituent stocks of the Hong Kong Stock Connect Innovative Drug ETF showed positive performance, with Lepu Biopharma rising over 5% and CSPC Pharmaceutical Group increasing over 3% [3]. - The index will be revised to exclude Contract Research Organizations (CROs), ensuring it reflects a 100% purity of innovative drugs, which are directly linked to drug commercialization success [5][6]. Group 3: Major Transactions - CSPC Pharmaceutical Group entered into a significant exclusive licensing agreement with Madrigal Pharmaceuticals, potentially worth up to 2.075 billion USD for the oral GLP-1 receptor agonist SYH2086 [6]. - China National Pharmaceutical Group's subsidiary is expected to receive a milestone payment of 300 million USD for a technology transfer related to a PD-1/VEGF dual antibody [7]. Group 4: Industry Drivers - The innovative drug sector is driven by three main factors: accelerated internationalization, supportive policies, and technological breakthroughs [8]. - Internationalization is highlighted by the increasing presence of domestic innovative drug data at international conferences and a rise in overseas business development transactions [8]. - Recent supportive policies for the innovative drug industry include measures to encourage investment and optimize procurement, indicating a new development cycle for the sector [8]. - Technological advancements in areas such as ADC, GLP-1, and immune-oncology are leading to significant innovations and market opportunities [8].